$SSII
SS Innovations International, Inc. Stock $ssii

$ssii Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000121390022069119 Filed on November 04, 2022

Income Statement

Concept	2022 Q4	2021 Q4	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$315.7K	$134.9K	$947.2K
YoY Change	134.12%	-83.4%	16.63%
Gross Profit	-$315.7K	-$134.9K	-$947.2K
YoY Change	134.12%	-83.4%	16.63%
Gross Profit Margin
Selling, General & Admin	$908.3K	$141.5K	$458.8K
YoY Change	541.8%	-123.12%	59.45%
% of Gross Profit
Research & Development	$72.96K	$0.00	$1.000K
YoY Change		-100.0%	-66.67%
% of Gross Profit
Depreciation & Amortization	$2.280K	$2.980K	$18.79K
YoY Change	-23.49%	-68.16%	-49.8%
% of Gross Profit
Operating Expenses	$981.2K	$141.5K	$1.407M
YoY Change	593.41%	-123.16%	27.57%
Operating Profit	-$1.297M	-$276.4K	-$2.354M
YoY Change	369.29%	37.46%	22.93%
Interest Expense	-$45.49K	$30.00	$120.00
YoY Change	-151733.33%	-137.5%	-88.67%
% of Operating Profit
Other Income/Expense, Net	$170.0K	-$77.39K	-$77.27K
YoY Change	-319.64%	273.86%	255.22%
Pretax Income	-$1.172M	-$353.7K	-$1.484M
YoY Change	231.46%	59.45%	31.98%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.172M	-$353.7K	-$1.484M
YoY Change	231.46%	59.45%	31.98%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.05
Diluted Earnings Per Share	-$0.02	-$10.73K	-$0.05
COMMON SHARES
Basic Shares Outstanding	39.20M shares		28.48M shares
Diluted Shares Outstanding			28.48M shares

Balance Sheet

Concept	2022 Q4	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.351M	$405.8K	$405.8K
YoY Change	233.04%	152.49%	152.49%
Cash & Equivalents	$1.351M	$405.8K	$405.8K
Short-Term Investments
Other Short-Term Assets	$8.680K	$2.290K	$2.290K
YoY Change	279.04%	0.0%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.360M	$408.1K	$408.1K
YoY Change	968.47%	150.35%	150.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.40K	$20.54K	$20.54K
YoY Change	-44.51%	-46.23%	-46.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$11.40K	$20.54K	$20.54K
YoY Change	-44.51%	-86.74%	-86.74%
TOTAL ASSETS
Total Short-Term Assets	$4.360M	$408.1K	$408.1K
Total Long-Term Assets	$11.40K	$20.54K	$20.54K
Total Assets	$4.371M	$428.6K	$428.6K
YoY Change	919.92%	34.84%	34.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$124.6K	$124.6K
YoY Change		-5.42%	-5.42%
Accrued Expenses	$5.700K	$17.70K	$17.70K
YoY Change	-67.8%	-90.62%	-97.94%
Deferred Revenue
YoY Change
Short-Term Debt	$4.000M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.051M	$287.3K	$287.3K
YoY Change	1310.2%	-75.8%	-75.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.051M	$287.3K	$287.3K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$4.051M	$287.3K	$287.3K
YoY Change	1310.2%	-75.8%	-75.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.69M	-$8.478M
YoY Change	26.1%	21.22%
Common Stock	$5.389K	$3.785K
YoY Change	42.38%	-99.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$26.00K
YoY Change
Treasury Stock Shares
Shareholders Equity	$320.2K	$141.3K	$141.3K
YoY Change
Total Liabilities & Shareholders Equity	$4.371M	$428.6K	$428.6K
YoY Change	919.92%	34.84%	34.84%

Cashflow Statement

Concept	2022 Q4	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$1.172M	-$353.7K	-$1.484M
YoY Change	231.46%	59.45%	31.98%
Depreciation, Depletion And Amortization	$2.280K	$2.980K	$18.79K
YoY Change	-23.49%	-68.16%	-49.8%
Cash From Operating Activities	-$1.132M	-$114.6K	-$363.0K
YoY Change	887.72%	1836.15%	300.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$1.900M	$26.00K	$38.15K
YoY Change	-7407.69%	-165.0%	-195.38%
Cash From Investing Activities	-$1.900M	$26.00K	$38.15K
YoY Change	-7407.69%	-165.0%	-186.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$26.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.869M	289.2K	$569.9K
YoY Change	1237.95%	40.42%	113.64%
NET CHANGE
Cash From Operating Activities	-1.132M	-114.6K	-$363.0K
Cash From Investing Activities	-1.900M	26.00K	$38.15K
Cash From Financing Activities	3.869M	289.2K	$569.9K
Net Change In Cash	837.2K	200.6K	$245.1K
YoY Change	317.4%	25.34%	85.33%
FREE CASH FLOW
Cash From Operating Activities	-$1.132M	-$114.6K	-$363.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Entity File Number EntityFileNumber	333-216054
CY2021	dei	Entity Registrant Name EntityRegistrantName	AVRA MEDICAL ROBOTICS, INC
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3478854
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	3259 Progress Drive
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 114
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32826
CY2021	dei	City Area Code CityAreaCode	(407)
CY2021	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware		usd
CY2020	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware		usd
CY2021	dei	Local Phone Number LocalPhoneNumber	956-2250
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2021	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment		usd
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39197099	shares
CY2021	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2021	dei	Auditor Firm AuditorFirmId	5041
CY2021	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	405774	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160709	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2291	usd
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2290	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	408065	usd
CY2020Q4	us-gaap	Assets Current AssetsCurrent	162999	usd
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	98592	usd
CY2020Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	98592	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	78050	usd
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	60385	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20542	usd
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38207	usd
CY2020Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	115542	usd
CY2021Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	36122	usd
CY2020Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	36122	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	36122	usd
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	35000	usd
CY2020Q4	us-gaap	Other Assets OtherAssets	1122	usd
CY2021Q4	us-gaap	Assets Assets	428607	usd
CY2020Q4	us-gaap	Assets Assets	317870	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	124581	usd
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	131719	usd
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	671500	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17700	usd
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	188700	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	145000	usd
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	195000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	287281	usd
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1186919	usd
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37848905	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37848905	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25721971	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25721971	shares
CY2021	avmr	Proceeds From Promissory Notes ProceedsFromPromissoryNotes		usd
CY2020	avmr	Proceeds From Securities Offering ProceedsFromSecuritiesOffering		usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3785	usd
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2572	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-849637	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	537829	usd
CY2021Q4	avmr	Common Stock Liability Common Stock To Be Issued CommonStockLiabilityCommonStockToBeIssued	4265295	shares
CY2020Q4	avmr	Common Stock Liability Common Stock To Be Issued CommonStockLiabilityCommonStockToBeIssued	289697	shares
CY2021Q4	avmr	Common Stock Liability CommonStockLiability	458519	usd
CY2020Q4	avmr	Common Stock Liability CommonStockLiability	100925	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8183082	usd
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6021201	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	26000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8478060	usd
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6993747	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	141326	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-869049	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	428607	usd
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	317870	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3000	usd
CY2021	avmr	Compensation Expense CompensationExpense	947237	usd
CY2020	avmr	Compensation Expense CompensationExpense	812190	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	458801	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	287737	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	1407038	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	1102927	usd
CY2020	avmr	Gain On Forgiveness Of Ppp Loan GainOnForgivenessOfPPPLoan	-4630	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-77392	usd
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	-25331	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	118	usd
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	6	usd
CY2020	us-gaap	Interest Expense InterestExpense	1059	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77274	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21754	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1484313	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1124681	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1484313	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1124681	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23372299	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1484313	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1124681	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18787	usd
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37431	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	767237	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	434180	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1107500	usd
CY2021	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	77392	usd
CY2020	us-gaap	Loss On Sale Of Investments LossOnSaleOfInvestments	25331	usd
CY2020	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	4630	usd
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-4000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-363034	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90540	usd
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	40000	usd
CY2020	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	4000	usd
CY2021	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	38150	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38150	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-44000	usd
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	130200	usd
CY2020	avmr	Proceeds From Promissory Notes ProceedsFromPromissoryNotes	65000	usd
CY2020	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	4630	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	315200	usd
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	194845	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12900	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2100	usd
CY2021	avmr	Proceeds From Securities Offering ProceedsFromSecuritiesOffering	267850	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	26000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	569949	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	266775	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	245065	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	132235	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160709	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28474	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	405774	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160709	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1059	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	118	usd
CY2021	avmr	Related Party Note Payable Converted To Common Stock RelatedPartyNotePayableConvertedToCommonStock	50000	usd
CY2020	avmr	Related Party Note Payable Converted To Common Stock RelatedPartyNotePayableConvertedToCommonStock	302700	usd
CY2020	avmr	Promissory Note Converted Into Common Stock PromissoryNoteConvertedIntoCommonStock	45000	usd
CY2020	us-gaap	Stock Issued1 StockIssued1	170000	usd
CY2021	avmr	Stock Issued For Equipment StockIssuedForEquipment	9543	usd
CY2020	avmr	Stock Issued For Equipment StockIssuedForEquipment	25000	usd
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1063258	usd
CY2020	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	412789	usd
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	29291	usd
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	195089	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2100	usd
CY2020	avmr	Stock Issued During Periods Value Issued For Services StockIssuedDuringPeriodsValueIssuedForServices	11449	usd
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	302700	usd
CY2020	avmr	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	194842	usd
CY2020	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	170000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1124681	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-869049	usd
CY2021	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	862849	usd
CY2021	avmr	Stock Issued During Periods Value Issued For Services StockIssuedDuringPeriodsValueIssuedForServices	869668	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	50000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	146273	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	276697	usd
CY2021	avmr	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	315200	usd
CY2021	avmr	Stock Issued During Period Treasury Stock StockIssuedDuringPeriodTreasuryStock	-26000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1484313	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	141326	usd
CY2021	avmr	Stockholders Deficit StockholdersDeficit	8400668	usd
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2021 and 2020, $147,460 and $0, respectively, were in excess of the FDIC insured limit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2021Q4	avmr	Fdic Insured FDICInsured	250000	usd
CY2021Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	147460	usd
CY2020Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2021	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2021	avmr	Purchased Medical Equipment PurchasedMedicalEquipment	75000	usd
CY2021Q4	avmr	Percentage Financed By The Seller PercentageFinancedByTheSeller	1	pure
CY2020Q1	avmr	Equipment Relieved Amount EquipmentRelievedAmount	25000	usd
CY2021	us-gaap	Related Parties Amount In Cost Of Sales RelatedPartiesAmountInCostOfSales	50000	usd
CY2018Q1	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	36000	usd
CY2018Q1	us-gaap	Goodwill Transfers GoodwillTransfers	14400	usd
CY2018Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	24000	shares
CY2019	us-gaap	Goodwill Transfers GoodwillTransfers	121.93	usd
CY2019	avmr	Amortized Of Straight Ine Method AmortizedOfStraightIneMethod	36000	usd
CY2019	us-gaap	Intermediate Life Plants Useful Life IntermediateLifePlantsUsefulLife	P3Y
CY2019	avmr	Amount Of Amortized AmountOfAmortized	121.93	usd
CY2021Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	102500	shares
CY2021Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	2.000000	usd
CY2020Q4	avmr	Shares Issued Price Per Shares SharesIssuedPricePerShares	1.5
CY2020Q4	avmr	Notes Total NotesTotal	202700	usd
CY2020Q4	avmr	Total Units TotalUnits	202700	shares
CY2020Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	810800	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	1013500	shares
CY2020Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.4
CY2021Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	384615	shares
CY2020Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	100000	usd
CY2020Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	1000000
CY2020Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1000000	shares
CY2020Q1	avmr	Common Stock Per Share CommonStockPerShare	0.1
CY2020Q4	avmr	Payroll Protection Loan Amount PayrollProtectionLoanAmount	4630	usd
CY2018	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2019-12-31
CY2019Q1	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2019-12-31
CY2019Q1	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2019-09-11
CY2019Q1	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2019-09-14
CY2019Q1	avmr	Number Of Warrants Purchase NumberOfWarrantsPurchase	12500	shares
CY2019Q1	avmr	Strike Price StrikePrice	1.25
CY2019Q1	avmr	Warrant Expiration Period WarrantExpirationPeriod	P3Y
CY2019Q1	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2019-09-29
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2643635	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1175000	shares
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	471825	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	912489	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4393785	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	221827	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q1	avmr	Number Of Shares Issued Upon Compensation NumberOfSharesIssuedUponCompensation	218000	shares
CY2017Q4	us-gaap	Share Price SharePrice	2
CY2018Q3	avmr	Number Of Common Stock Sold NumberOfCommonStockSold	16000	shares
CY2018Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	20000	usd
CY2018Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	400	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	115050	shares
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.25
CY2019Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	95050	shares
CY2019Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	79672	shares
CY2019Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	600000	shares
CY2019Q4	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	250000	shares
CY2020Q4	avmr	Description Of Avra Issued An Aggregate DescriptionOfAVRAIssuedAnAggregate	On November 6, 2020, AVRA issued an aggregate 256,027 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share; and (c) a 0.00008749_% limited liability company membership interest in Avra Air, LLC (“Avra Air”), a development stage company, which interest may be put to the Company at the option of the investor for a period of two years from issuance, in exchange for one Share. As a result of the foregoing, the investors were issued an aggregate of 1,024,108 Shares, warrants to purchase 1,280,135 Shares and a 22.4% limited liability company membership interest in Avra Air, LLC.
CY2020Q4	avmr	Commitment To Sell CommitmentToSell	135000	shares
CY2020Q4	avmr	Commitment To Sell Units CommitmentToSellUnits	135000	usd
CY2020Q4	avmr	Promissory Notes Value PromissoryNotesValue	25000	usd
CY2020Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	1027	usd
CY2020Q4	avmr	Commitment Units CommitmentUnits	26027	shares
CY2020Q4	avmr	Number Of Shares Issued Upon Compensation NumberOfSharesIssuedUponCompensation	321489	shares
CY2022Q4	avmr	Shares For A Stock Option Exercised SharesForAStockOptionExercised	21000	shares
CY2022Q4	avmr	Exercise Price Per Share ExercisePricePerShare	0.1
CY2020	avmr	Shares Of Common Stock SharesOfCommonStock	1810800	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	378378	shares
CY2021Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	629375	shares
CY2021Q4	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	3619817	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	174553	shares
CY2016Q3	avmr	Employment Agreements Description EmploymentAgreementsDescription	On August 1, 2016, the Company entered into a three-year Employment Agreement with its Vice President of Global Business Development. The agreement provides for an annual salary of $96,000 per year, increasing to $144,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 100,000 shares vested on each yearly anniversary.
CY2021	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-05-01
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.25
CY2020Q3	avmr	Employee Agreement Term EmployeeAgreementTerm	P48M
CY2020Q3	us-gaap	Salaries And Wages SalariesAndWages	15000	usd
CY2021Q4	us-gaap	Public Utilities Property Plant And Equipment Vehicles PublicUtilitiesPropertyPlantAndEquipmentVehicles	500	usd
CY2020Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	1000000	shares
CY2020Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.25
CY2018Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1829.25	usd
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	2454.75	usd
CY2019Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2223	usd
CY2020Q2	avmr	Rent Lease Agreement RentLeaseAgreement	0.50	pure
CY2020Q2	avmr	Rent Lease Agreement RentLeaseAgreement	0.50	pure
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1474.17	usd
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1964.74	usd
CY2021	avmr	Issued Discount IssuedDiscount	0.10	pure
CY2021	avmr	Conversion Amount ConversionAmount	100000000	usd
CY2021	avmr	Convertible Notedescription ConvertibleNotedescription	In order to fund the Interim Financing, the Company offered and sold to two accredited investors, $1,000,000 and $100,000 one-year convertible promissory notes (the “Convertible Notes”). The Convertible Notes will have the same interest rate and payment terms as the Cardio Notes and otherwise be substantially similar to the Cardio Notes, provided, however, that the Convertible Notes do not have an original issue discount. Further, upon consummation of the Transaction (if and when it is consummated) the Convertible Notes will automatically convert into a number of AVRA Shares determined by dividing the principal amount of the Convertible Notes by $100 million and multiplying such number expressed as a percentage by the number of AVRA Shares issued to Dr. Srivastava and the other shareholders of the SSI Parties (if any) upon closing of the Transaction. The Company may offer and sell up to an aggregate principal amount of $5,000,000 in Convertible Notes in order to fund the Interim Financing.
CY2022Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	52000	shares
CY2021Q4	us-gaap	Other Assets OtherAssets		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28480973	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28480973	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23372299	shares
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2021	avmr	Equipment Acquisition Included In Accounts Payable EquipmentAcquisitionIncludedInAccountsPayable		usd
CY2020	avmr	Equipment Acquisition Included In Accounts Payable EquipmentAcquisitionIncludedInAccountsPayable		usd
CY2021	avmr	Promissory Note Converted Into Common Stock PromissoryNoteConvertedIntoCommonStock		usd
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001676163
CY2021Q2	dei	Entity Public Float EntityPublicFloat	0	usd

Files In Submission

Name	View Source	Status
0001213900-22-069119-index-headers.html	Edgar Link	pending
0001213900-22-069119-index.html	Edgar Link	pending
0001213900-22-069119.txt	Edgar Link	pending
0001213900-22-069119-xbrl.zip	Edgar Link	pending
avmr-20211231.xsd	Edgar Link	pending
f10k2021ex31-1_avramedical.htm	Edgar Link	pending
f10k2021ex31-2_avramedical.htm	Edgar Link	pending
f10k2021_avramedical.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
avmr-20211231_cal.xml	Edgar Link	unprocessable
avmr-20211231_def.xml	Edgar Link	unprocessable
avmr-20211231_lab.xml	Edgar Link	unprocessable
avmr-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2021_avramedical_htm.xml	Edgar Link	completed
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSII
SS Innovations International, Inc. Stock $ssii

2022 Q4 Form 10-K Financial Statement

#000121390022069119 Filed on November 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSII SS Innovations International, Inc. Stock $ssii

2022 Q4 Form 10-K Financial Statement

#000121390022069119 Filed on November 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSII
SS Innovations International, Inc. Stock $ssii